Taimakon MDMA da aka ba da taimako ya wuce babban gwaji: 67% na marasa lafiyar PTSD sun sami raguwa

ƙofar druginc

Taimakon MDMA da aka ba da taimako ya wuce babban gwaji: 67% na marasa lafiyar PTSD sun sami raguwa

Shahararren mai ba da magani na MDMA ya ci gaba da tafiya cikin manyan tashoshin asibiti tare da nasarar nasarar binciken kashi na 3 na farko don mahaukatan mahaukata. Wani sabon bincike ya nuna cewa MDMA, wanda aka sani da suna Ecstasy ko Molly, ya kasance mai tasiri don inganta alamun bayyanar cututtukan damuwa bayan tashin hankali (PTSD). Marasa lafiya na gwaji sun sami sakamako mai kyau ta hanyar ƙara magungunan psychoactive zuwa psychotherapy.

A cikin gwajin gwajin da aka samu na manya 90 tare da mai tsanani PTSD, waɗanda suka gan shi MDMApharmacotherapy da psychotherapy sun sami ci gaba mai mahimmanci a cikin alamun PTSD kamar yadda aka auna ta da likitan-amfani CAPS-5 Jimlar Matsakaicin Totalari a kan waɗanda kawai suka karɓi placebo da psychotherapy.

An gano cewa kashi 67 cikin dari na mahalarta masu fama da rikice-rikicen rikice-rikice na yau da kullun ba su cancanci ganewar asali ba bayan zaman MDMA guda uku na maganin magana. A cikin duka, 88 bisa dari na mahalarta sun sami raguwa sosai a cikin bayyanar cututtuka.

A ranar Litinin, Mungiyar Multidisciplinary Association of Psychedelic Studies ta ba da sakamakon binciken ta, wanda ya gano cewa kashi 67 cikin ɗari na mahalarta da ke fama da matsananciyar damuwa bayan tashin hankali ba su cancanci a gano su ba bayan zaman tattaunawa na MDMA sau uku.

A cikin duka, 88 bisa dari na mahalarta sun sami raguwa sosai a cikin bayyanar cututtuka.

Masu binciken suna da begen cewa binciken zai taimaka wajen samun nasarar da aka nuna wacce Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da ita a shekarar 2023. Karatuttukan nazarin lokaci na 3 ya maimaita kuma ya fadada akan sakamako na 2 na zamani, yana nuna cewa hanyar na iya zama magani mai tasiri da tsada don PTSD saboda kowane dalili.

A cikin bayanin, babban marubucin ya nuna sakamako ga mutanen da ke da ƙananan nau'in PTSD, waɗanda ke baƙin ciki ko waɗanda suka ba da rahoton tarihin giya ko amfani da abu.

“Mutanen da ke da cututtukan da ke da wahalar-magani, waɗanda galibi ana ɗaukarsu ba su da matsala, suna amsa daidai da wannan sabon maganin kamar sauran mahalarta binciken. A zahiri, mahalarta da aka bincikar su da nau'in rarrabawar PTSD sun sami raguwar alamomi fiye da waɗanda ba su da rukunin rarrabawar. ”

MDMA ance zata iya zama sanadiyar farfadowa inda aka bayyana cewa sinadarin hanya ce ta gwaji wacce ke bukatar hankali da saiti domin samun sakamako mai kyau.

"Duk da yake yawancin nau'ikan maganin PTSD sun haɗa da tuno da cutar da ta gabata, mai yiwuwa ikon MDMA na musamman don haɓaka jinƙai da fahimta yayin rage damuwa yana ba shi damar yin tasiri."

An gabatar da gwajin na 3 ne ta MAPS Jama'a mai Amfani da Jama'a, wani kamfanin mallakar MAPS ne wanda aka mayar da hankali kan ci gaba da bincike kan tabin hankali.

Masu bincike sun tattara kuma sun bi da mutanen 90 da ke fama da matsanancin ciwo, mai tsanani PTSD. Rabin mahalarta sun karɓi zama uku na MDMA ko placebo, tare da maganin magana.

Masu shiga cikin binciken MDMA a matsakaita sun sha wahala daga PTSD tsawon shekaru 14

Bayan jiyya, kashi 67 cikin ɗari na mutane - waɗanda suka wahala daga PTSD na kimanin shekaru 14 - ba su da wata alama ko kaɗan, yayin da kashi 88 cikin XNUMX ba su da alamomi kaɗan.

Abubuwan binciken sun hada da mutane tare da PTSD sakamakon yaƙi da abubuwan da suka shafi faɗa, haɗari, da cin zarafi - kashi 84 cikin ɗari na mahalarta suna da tarihin raunin yara.

Masu shiga cikin binciken MDMA a matsakaici sun sha wahala daga PTSD tsawon shekaru 14 (fig.)
Masu shiga cikin binciken na MDMA sun sha wahala daga PTSD na kimanin shekaru 14 (fig.)

A cewar bayanin, MDMA bai kara yawan tunanin kashe kansa ko halayya ba kuma bai kara hadarin zuciya da jijiyoyin jini ba idan aka kwatanta shi da magani tare da placebo.

MDMA ta jera ta FDA a matsayin Jadawalin I magani, wanda aka bayyana ba shi da fa'idodin likita. Yana da izinin doka kawai ta hanyar karatun asibiti.

"A sakamakon wannan binciken, kuma ta hanyar ci gaba da daidaitaccen aikace-aikacen rigakafin kimiyya, mun nuna cewa maganin MDMA da ke taimakawa na iya samar da taimako ga mutanen da aka gano tare da PTSD."

Mataki na biyu na gwaji na 3 a halin yanzu yana rajistar mahalarta.

Gabanin fatan da ake da shi na amincewa da MDMA mai taimakawa PTSD far a 2023, FDA ta share fadada shirin samun damar inda marasa lafiya 50 za su iya karɓar magani.

MAPS na shirin gudanar da ƙarin karatu don bincika yiwuwar magance wasu cututtukan ƙwaƙwalwa, kuma tare da wasu ladabi na magani kamar maganin rukuni da kuma fahimtar halayyar halayyar ma'aurata.

Tushen ao MAPS (EN), Shafin Yanar Gizo a Yau (EN,, MuggleHead (EN), KalmarKa (EN), ZME Kimiyya (EN)

Shafuka masu dangantaka

Bar sharhi

[banner = "89"]